{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T20:50:33Z","timestamp":1791665433321,"version":"4.3.4"},"reference-count":101,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T00:00:00Z","timestamp":1789776000000},"content-version":"vor","delay-in-days":261,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004836","name":"Danmarks Frie Forskningsfond","doi-asserted-by":"publisher","award":["2096-00067B"],"award-info":[{"award-number":["2096-00067B"]}],"id":[{"id":"10.13039\/501100004836","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Treatment and Research Communications"],"published-print":{"date-parts":[[2026]]},"DOI":"10.1016\/j.ctarc.2026.101453","type":"journal-article","created":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T23:50:36Z","timestamp":1791589836000},"page":"101453","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["The prognostic value of HER2 in gastroesophageal adenocarcinoma \u2013 a meta-analysis"],"prefix":"10.1016","volume":"49","author":[{"given":"Kristian","family":"Egebjerg","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan Tr\u00f8st","family":"J\u00f8rgensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael Charles","family":"Sachs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morten","family":"Mau-S\u00f8rensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ctarc.2026.101453_bib0001","doi-asserted-by":"crossref","first-page":"137","DOI":"10.7150\/jca.4090","article-title":"HER2 as a prognostic marker in gastric cancer - A systematic analysis of data from the literature","volume":"3","author":"J\u00f8rgensen","year":"2012","journal-title":"J. Cancer"},{"key":"10.1016\/j.ctarc.2026.101453_bib0002","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1038\/s41571-019-0268-3","article-title":"HER2-targeted therapies - a role beyond breast cancer","volume":"17","author":"Oh","year":"2020","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.ctarc.2026.101453_bib0003","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/S0140-6736(10)61121-X","article-title":"Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial","volume":"376","author":"Bang","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.ctarc.2026.101453_bib0004","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1038\/s41591-024-02992-x","article-title":"Trastuzumab deruxtecan in HER2-positive advanced gastric cancer: exploratory biomarker analysis of the randomized, phase 2 DESTINY-Gastric01 trial","volume":"30","author":"Shitara","year":"2024","journal-title":"Nat. Med."},{"key":"10.1016\/j.ctarc.2026.101453_bib0005","doi-asserted-by":"crossref","first-page":"2033","DOI":"10.1158\/1078-0432.CCR-18-2275","article-title":"Advances in HER2-targeted therapy: novel agents and opportunities beyond breast and gastric cancer","volume":"25","author":"Meric-Bernstam","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ctarc.2026.101453_bib0006","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1126\/science.3798106","article-title":"Human breast cancer: correlation of relapse and survival with amplification of the HER-2\/neu oncogene","volume":"235","author":"Slamon","year":"1987","journal-title":"Science"},{"key":"10.1016\/j.ctarc.2026.101453_bib0007","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1634\/theoncologist.2008-0230","article-title":"The HER-2 receptor and breast cancer: ten years of targeted anti-HER-2 therapy and personalized medicine","volume":"14","author":"Ross","year":"2009","journal-title":"Oncologist"},{"key":"10.1016\/j.ctarc.2026.101453_bib0008","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1007\/s12094-017-1711-5","article-title":"An independent survival prognostic role for human epidermal growth factor receptor 2 in gastric cancer: evidence from a meta-analysis","volume":"20","author":"Wang","year":"2018","journal-title":"Clin. Transl. Oncol."},{"key":"10.1016\/j.ctarc.2026.101453_bib0009","doi-asserted-by":"crossref","first-page":"5992","DOI":"10.1158\/1078-0432.CCR-12-1318","article-title":"Impact of expression of human epidermal growth factor receptors EGFR and ERBB2 on survival in stage II\/III gastric cancer","volume":"18","author":"Terashima","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ctarc.2026.101453_bib0010","doi-asserted-by":"crossref","first-page":"2070","DOI":"10.1016\/j.humpath.2012.02.017","article-title":"Approaching heterogeneity of human epidermal growth factor receptor 2 in surgical specimens of gastric cancer","volume":"43","author":"Asioli","year":"2012","journal-title":"Hum. Pathol."},{"key":"10.1016\/j.ctarc.2026.101453_bib0011","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/j.prp.2013.04.017","article-title":"Significance of TFF3 protein and her-2\/neu status in patients with gastric adenocarcinoma","volume":"209","author":"Xu","year":"2013","journal-title":"Pathol. Res. Pract."},{"key":"10.1016\/j.ctarc.2026.101453_bib0012","doi-asserted-by":"crossref","DOI":"10.1186\/s12885-018-5242-4","article-title":"HER2\/neu (ERBB2) expression and gene amplification correlates with better survival in esophageal adenocarcinoma","volume":"19","author":"Plum","year":"2019","journal-title":"BMC Cancer"},{"key":"10.1016\/j.ctarc.2026.101453_bib0013","first-page":"1034","article-title":"Evaluation of immunoreactivity for erbB-2 protein as a marker of poor short term prognosis in gastric cancer","volume":"51","author":"Yonemura","year":"1991","journal-title":"Cancer Res."},{"key":"10.1016\/j.ctarc.2026.101453_bib0014","doi-asserted-by":"crossref","first-page":"5315","DOI":"10.1007\/s13277-014-1693-7","article-title":"Prognostic significance of HER2 expression based on trastuzumab for gastric cancer (ToGA) criteria in gastric cancer: an updated meta-analysis","volume":"35","author":"Gu","year":"2014","journal-title":"Tumour Biol."},{"key":"10.1016\/j.ctarc.2026.101453_bib0015","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.ctarc.2026.101453_bib0016","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1002742","article-title":"COSMOS-E: guidance on conducting systematic reviews and meta-analyses of observational studies of etiology","volume":"16","author":"Dekkers","year":"2019","journal-title":"PLoS Med."},{"key":"10.1016\/j.ctarc.2026.101453_bib0017","doi-asserted-by":"crossref","first-page":"1","DOI":"10.18637\/jss.v036.i03","article-title":"Conducting meta-analyses in R with the metafor package","volume":"36","author":"Viechtbauer","year":"2010","journal-title":"J. Stat. Softw."},{"key":"10.1016\/j.ctarc.2026.101453_bib0018","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/S0046-8177(00)80195-1","article-title":"HER-2\/neu gene amplification by FISH predicts poor survival in Barrett\u2019s esophagus-associated adenocarcinoma","volume":"31","author":"Brien","year":"2000","journal-title":"Hum. Pathol."},{"key":"10.1016\/j.ctarc.2026.101453_bib0019","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1093\/jjco\/hyg039","article-title":"Prognostic significance of p53, nm23, PCNA and c-erbB-2 in gastric cancer","volume":"33","author":"Lee","year":"2003","journal-title":"Jpn. J. Clin. Oncol."},{"key":"10.1016\/j.ctarc.2026.101453_bib0020","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1111\/j.1365-2559.2004.01852.x","article-title":"Clinicopathological significance and survival influence of p53 protein expression in gastric carcinoma","volume":"44","author":"Pinto-De-Sousa","year":"2004","journal-title":"Histopathology"},{"key":"10.1016\/j.ctarc.2026.101453_bib0021","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1007\/s10620-005-9057-1","article-title":"HER-2\/neu amplification is an independent prognostic factor in gastric cancer","volume":"51","author":"Il Park","year":"2006","journal-title":"Dig. Dis. Sci."},{"key":"10.1016\/j.ctarc.2026.101453_bib0022","doi-asserted-by":"crossref","first-page":"3022","DOI":"10.1158\/1078-0432.CCR-07-1898","article-title":"Impact of insulin-like growth factor type 1 receptor, epidermal growth factor receptor, and HER2 expressions on outcomes of patients with gastric cancer","volume":"14","author":"Matsubara","year":"2008","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ctarc.2026.101453_bib0023","doi-asserted-by":"crossref","first-page":"7843","DOI":"10.1158\/1078-0432.CCR-08-1064","article-title":"High expression of HER3 is associated with a decreased survival in gastric cancer","volume":"14","author":"Hayashi","year":"2008","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ctarc.2026.101453_bib0024","doi-asserted-by":"crossref","first-page":"2112","DOI":"10.1007\/s00268-009-0142-z","article-title":"Comparative study on overexpression of HER2\/neu and HER3 in gastric cancer","volume":"33","author":"Zhang","year":"2009","journal-title":"World J. Surg."},{"key":"10.1016\/j.ctarc.2026.101453_bib0025","doi-asserted-by":"crossref","first-page":"559","DOI":"10.3892\/ol_00000099","article-title":"Simultaneous detection of expression and gene mutations of HER2\/neu in Chinese patients with gastric cancer","volume":"1","author":"Zhang","year":"2010","journal-title":"Oncol. Lett."},{"key":"10.1016\/j.ctarc.2026.101453_bib0026","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1038\/modpathol.2011.52","article-title":"Assessment of ErbB2 (Her2) in oesophageal adenocarcinomas: summary of a revised immunohistochemical evaluation system, bright field double in situ hybridisation and fluorescence in situ hybridisation","volume":"24","author":"Langer","year":"2011","journal-title":"Mod. Pathol."},{"key":"10.1016\/j.ctarc.2026.101453_bib0027","doi-asserted-by":"crossref","first-page":"2833","DOI":"10.1245\/s10434-011-1695-2","article-title":"Evaluation of HER2 protein expression in gastric carcinomas: comparative analysis of 1414 cases of whole-tissue sections and 595 cases of tissue microarrays","volume":"18","author":"Kim","year":"2011","journal-title":"Ann. Surg. Oncol."},{"key":"10.1016\/j.ctarc.2026.101453_bib0028","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0023985","article-title":"Discovery of new molecular subtypes in oesophageal adenocarcinoma","volume":"6","author":"Berg","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.ctarc.2026.101453_bib0029","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1007\/s10120-012-0179-9","article-title":"Prognosis of patients with advanced gastric cancer by HER2 status and trastuzumab treatment","volume":"16","author":"Shitara","year":"2013","journal-title":"Gastric Cancer"},{"key":"10.1016\/j.ctarc.2026.101453_bib0030","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1158\/1078-0432.CCR-11-2272","article-title":"Association of HER2\/ErbB2 expression and gene amplification with pathologic features and prognosis in esophageal adenocarcinomas","volume":"18","author":"Yoon","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ctarc.2026.101453_bib0031","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1136\/jclinpath-2011-200345","article-title":"HER2 status in unusual histological variants of gastric adenocarcinomas","volume":"65","author":"Giuffr\u00e8","year":"2012","journal-title":"J. Clin. Pathol."},{"key":"10.1016\/j.ctarc.2026.101453_bib0032","doi-asserted-by":"crossref","first-page":"6577","DOI":"10.3748\/wjg.v18.i45.6577","article-title":"Alterations in the human epidermal growth factor receptor 2-phosphatidylinositol 3-kinase-v-Akt pathway in gastric cancer","volume":"18","author":"Sukawa","year":"2012","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.ctarc.2026.101453_bib0033","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1136\/jclinpath-2012-200774","article-title":"HER2\/neu testing for anti-HER2-based therapies in patients with unresectable and\/or metastatic gastric cancer","volume":"65","author":"G\u00f3mez-Martin","year":"2012","journal-title":"J. Clin. Pathol."},{"key":"10.1016\/j.ctarc.2026.101453_bib0034","doi-asserted-by":"crossref","first-page":"2656","DOI":"10.1093\/annonc\/mds104","article-title":"Prognosis of metastatic gastric and gastroesophageal junction cancer by HER2 status: a European and USA International collaborative analysis","volume":"23","author":"Janjigian","year":"2012","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ctarc.2026.101453_bib0035","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/j.biopha.2012.03.002","article-title":"Leptin and HER-2 are associated with gastric cancer progression and prognosis of patients","volume":"66","author":"Geng","year":"2012","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.ctarc.2026.101453_bib0036","doi-asserted-by":"crossref","first-page":"2360","DOI":"10.1093\/annonc\/mdt232","article-title":"HER2 status in gastric cancers: a retrospective analysis from four Chinese representative clinical centers and assessment of its prognostic significance","volume":"24","author":"Sheng","year":"2013","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ctarc.2026.101453_bib0037","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0063458","article-title":"Serum HER 2 extracellular domain level is correlated with tissue HER 2 status in metastatic gastric or gastro-oesophageal junction adenocarcinoma","volume":"8","author":"Dai","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.ctarc.2026.101453_bib0038","doi-asserted-by":"crossref","first-page":"559","DOI":"10.3892\/ol.2012.1031","article-title":"The incidence and prognostic value of HER2 overexpression and cyclin D1 expression in patients with gastric or gastroesophageal junction adenocarcinoma in Israel","volume":"5","author":"Bar-Sela","year":"2013","journal-title":"Oncol. Lett."},{"key":"10.1016\/j.ctarc.2026.101453_bib0039","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1111\/j.1442-2050.2012.01369.x","article-title":"Clinicopathologic features and treatment outcomes of patients with human epidermal growth factor receptor 2-positive adenocarcinoma of the esophagus and gastroesophageal junction","volume":"26","author":"Phillips","year":"2013","journal-title":"Dis. Esophagus"},{"key":"10.1016\/j.ctarc.2026.101453_bib0040","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1007\/s12094-012-0921-0","article-title":"Prognostic significance of c-erbB2 overexpression in patients with metastatic gastric cancer","volume":"15","author":"Bayrak","year":"2013","journal-title":"Clin. Transl. Oncol."},{"key":"10.1016\/j.ctarc.2026.101453_bib0041","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1111\/cts.12043","article-title":"Clinical significance of vimentin expression and her-2 status in patients with gastric carcinoma","volume":"6","author":"Zhao","year":"2013","journal-title":"Clin. Transl. Sci."},{"key":"10.1016\/j.ctarc.2026.101453_bib0042","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1093\/annonc\/mds622","article-title":"Effect of HER2 on prognosis and benefit from peri-operative chemotherapy in early oesophago-gastric adenocarcinoma in the MAGIC trial","volume":"24","author":"Okines","year":"2013","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ctarc.2026.101453_bib0043","article-title":"Flotillin2 Expression correlates with HER2 levels and poor prognosis in gastric cancer","volume":"8","author":"Zhu","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.ctarc.2026.101453_bib0044","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1093\/annonc\/mds640","article-title":"The significance of the HER-2 status in esophageal adenocarcinoma for survival: an immunohistochemical and an in situ hybridization study","volume":"24","author":"Prins","year":"2013","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ctarc.2026.101453_bib0045","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1007\/s00595-013-0544-2","article-title":"Human epidermal growth factor receptor 2 (Her-2) and S-1 adjuvant chemotherapy in stage 2\/3 gastric cancer patients who underwent D2 gastrectomy","volume":"43","author":"Aoyama","year":"2013","journal-title":"Surg. Today"},{"key":"10.1016\/j.ctarc.2026.101453_bib0046","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1093\/annonc\/mds506","article-title":"A clinical-biological risk stratification model for resected gastric cancer: prognostic impact of Her2, Fhit, and APC expression status","volume":"24","author":"Bria","year":"2013","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ctarc.2026.101453_bib0047","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1002\/jso.23456","article-title":"HER2 in resected gastric cancer: is there prognostic value?","volume":"109","author":"Fisher","year":"2014","journal-title":"J. Surg. Oncol."},{"key":"10.1016\/j.ctarc.2026.101453_bib0048","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1007\/s10238-013-0261-6","article-title":"Clinical significance and positive correlation of FoxM1 and her-2 expression in gastric cancer","volume":"14","author":"Li","year":"2014","journal-title":"Clin. Exp. Med."},{"key":"10.1016\/j.ctarc.2026.101453_bib0049","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1007\/s10120-013-0239-9","article-title":"Evaluation of HER2-based biology in 1006 cases of gastric cancer in a Japanese population","volume":"17","author":"Aizawa","year":"2014","journal-title":"Gastric Cancer"},{"key":"10.1016\/j.ctarc.2026.101453_bib0050","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1471-2407-14-823","article-title":"Lauren classification combined with HER2 status is a better prognostic factor in Chinese gastric cancer patients","volume":"14","author":"Qiu","year":"2014","journal-title":"BMC Cancer"},{"key":"10.1016\/j.ctarc.2026.101453_bib0051","doi-asserted-by":"crossref","first-page":"2468","DOI":"10.1002\/ijc.28559","article-title":"HER2-positive patients receiving trastuzumab treatment have a comparable prognosis with HER2-negative advanced gastric cancer patients: a prospective cohort observation","volume":"134","author":"Qiu","year":"2014","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.ctarc.2026.101453_bib0052","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s12032-014-0280-5","article-title":"Prognosis significance of HER2 status and TACC1 expression in patients with gastric carcinoma","volume":"31","author":"Lv","year":"2014","journal-title":"Med. Oncol."},{"key":"10.1016\/j.ctarc.2026.101453_bib0053","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1016\/j.humpath.2014.02.006","article-title":"ARID1A\/BAF250a as a prognostic marker for gastric carcinoma: a study of 2 cohorts","volume":"45","author":"Wiegand","year":"2014","journal-title":"Hum. Pathol."},{"key":"10.1016\/j.ctarc.2026.101453_bib0054","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.clinre.2014.06.019","article-title":"HER2\/neu over-expression predicts poor outcome in early gastric cancer without lymph node metastasis","volume":"39","author":"Yan","year":"2015","journal-title":"Clin. Res. Hepatol. Gastroenterol."},{"key":"10.1016\/j.ctarc.2026.101453_bib0055","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1007\/s10120-014-0398-3","article-title":"HER2 expression in locally advanced gastric cancer with extensive lymph node (bulky N2 or paraaortic) metastasis (JCOG1005-A trial","volume":"18","author":"Matsumoto","year":"2015","journal-title":"Gastric Cancer"},{"key":"10.1016\/j.ctarc.2026.101453_bib0056","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1007\/s10120-014-0430-7","article-title":"Multicenter large-scale study of prognostic impact of HER2 expression in patients with resectable gastric cancer","volume":"18","author":"Kurokawa","year":"2015","journal-title":"Gastric Cancer"},{"key":"10.1016\/j.ctarc.2026.101453_bib0057","doi-asserted-by":"crossref","first-page":"3001","DOI":"10.1007\/s13277-014-2933-6","article-title":"TFF3 and HER2 expression and their correlation with survival in gastric cancer","volume":"36","author":"Gu","year":"2015","journal-title":"Tumor Biol."},{"key":"10.1016\/j.ctarc.2026.101453_bib0058","first-page":"1","article-title":"Correlations of Human epithelial growth factor receptor 2 overexpression with MUC2, MUC5AC, MUC6, p53, and clinicopathological characteristics in gastric cancer patients with curative resection","volume":"2015","author":"Park","year":"2015","journal-title":"Gastroenterol. Res. Pract."},{"key":"10.1016\/j.ctarc.2026.101453_bib0059","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1007\/s00432-016-2184-6","article-title":"Serum levels of soluble programmed cell death ligand 1 as a prognostic factor on the first-line treatment of metastatic or recurrent gastric cancer","volume":"142","author":"Takahashi","year":"2016","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"10.1016\/j.ctarc.2026.101453_bib0060","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1007\/s10120-015-0471-6","article-title":"Prognostic impact of HER2, EGFR, and c-MET status on overall survival of advanced gastric cancer patients","volume":"19","author":"Fuse","year":"2016","journal-title":"Gastric Cancer"},{"key":"10.1016\/j.ctarc.2026.101453_bib0061","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1007\/s10120-015-0504-1","article-title":"Metabolic landscape of advanced gastric cancer according to HER2 and its prognostic implications","volume":"19","author":"Ock","year":"2016","journal-title":"Gastric Cancer"},{"key":"10.1016\/j.ctarc.2026.101453_bib0062","doi-asserted-by":"crossref","first-page":"5406","DOI":"10.3748\/wjg.v22.i23.5406","article-title":"Association of HER2 status with prognosis in gastric cancer patients undergoing R0 resection: a large-scale multicenter study in China","volume":"22","author":"Shen","year":"2016","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.ctarc.2026.101453_bib0063","doi-asserted-by":"crossref","first-page":"5919","DOI":"10.2147\/OTT.S111778","article-title":"The coexpression and prognostic significance of c-MET, fibroblast growth factor receptor 2, and human epidermal growth factor receptor 2 in resected gastric cancer: a retrospective study","volume":"9","author":"Jia","year":"2016","journal-title":"Onco Targets Ther."},{"key":"10.1016\/j.ctarc.2026.101453_bib0064","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1038\/bjc.2017.122","article-title":"Nomogram-based prediction of survival in patients with advanced oesophagogastric adenocarcinoma receiving first-line chemotherapy: a multicenter prospective study in the era of trastuzumab","volume":"116","author":"Custodio","year":"2017","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.ctarc.2026.101453_bib0065","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1007\/s10120-016-0639-8","article-title":"Prognostic significance of performing universal HER2 testing in cases of advanced gastric cancer","volume":"20","author":"Jim\u00e9nez-Fonseca","year":"2017","journal-title":"Gastric Cancer"},{"key":"10.1016\/j.ctarc.2026.101453_bib0066","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1007\/s12094-016-1523-z","article-title":"Impact of HER2 expression on outcome in gastric cancer patients with liver metastasis","volume":"19","author":"Jiang","year":"2017","journal-title":"Clin. Transl. Oncol."},{"key":"10.1016\/j.ctarc.2026.101453_bib0067","doi-asserted-by":"crossref","first-page":"7407","DOI":"10.3748\/wjg.v23.i41.7407","article-title":"Survival analysis based on human epidermal growth factor 2 status in stage II-III gastric cancer","volume":"23","author":"Cho","year":"2017","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.ctarc.2026.101453_bib0068","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12885-017-3851-y","article-title":"Positive prognostic value of HER2-HER3 co-expression and p-mTOR in gastric cancer patients","volume":"17","author":"Cao","year":"2017","journal-title":"BMC Cancer"},{"key":"10.1016\/j.ctarc.2026.101453_bib0069","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1159\/000464250","article-title":"Expression of the ERBB Family of ligands and receptors in gastric cancer","volume":"84","author":"Byeon","year":"2017","journal-title":"Pathobiology"},{"key":"10.1016\/j.ctarc.2026.101453_bib0070","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1007\/s10120-016-0625-1","article-title":"Assessment of HER2 status in patients with gastroesophageal adenocarcinoma treated with epirubicin-based chemotherapy: heterogeneity-related issues and prognostic implications","volume":"20","author":"Personeni","year":"2017","journal-title":"Gastric Cancer"},{"key":"10.1016\/j.ctarc.2026.101453_bib0071","doi-asserted-by":"crossref","first-page":"731","DOI":"10.3233\/CBM-170865","article-title":"EGFR and AKT1 overexpression are mutually exclusive and associated with a poor survival in resected gastric adenocarcinomas","volume":"21","author":"Petrini","year":"2018","journal-title":"Cancer Biomark."},{"key":"10.1016\/j.ctarc.2026.101453_bib0072","first-page":"5185","article-title":"Significance and prognostic role of human epidermal growth factor receptor 2 and RAB1A expression in gastric cancer","volume":"15","author":"Xu","year":"2018","journal-title":"Oncol. Lett."},{"key":"10.1016\/j.ctarc.2026.101453_bib0073","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-017-17435-6","article-title":"Correlation of Gli1 and HER2 expression in gastric cancer: identification of novel target","volume":"8","author":"Shao","year":"2018","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ctarc.2026.101453_bib0074","doi-asserted-by":"crossref","first-page":"S311","DOI":"10.4103\/0973-1482.235348","volume":"14","author":"Xu","year":"2018","journal-title":"J. Cancer Res. Ther."},{"key":"10.1016\/j.ctarc.2026.101453_bib0075","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2020.01608","article-title":"The role of HER2 in self-renewal, invasion, and tumorigenicity of gastric cancer stem cells","volume":"10","author":"Sun","year":"2020","journal-title":"Front. Oncol."},{"key":"10.1016\/j.ctarc.2026.101453_bib0076","doi-asserted-by":"crossref","DOI":"10.1016\/j.prp.2019.152675","article-title":"Differential expression of HER2 and downstream proteins in prediction of advanced tumor phenotypes and overall survival of patients with Epstein-Barr virus-positive vs. negative gastric cancers","volume":"215","author":"Zhang","year":"2019","journal-title":"Pathol. Res. Pract."},{"key":"10.1016\/j.ctarc.2026.101453_bib0077","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12957-019-1652-2","article-title":"Prognostic significance of Human epidermal growth factor receptor-2 expression in patients with resectable gastric adenocarcinoma","volume":"17","author":"Kim","year":"2019","journal-title":"World J. Surg. Oncol."},{"key":"10.1016\/j.ctarc.2026.101453_bib0078","first-page":"3003","article-title":"NDRG1 suppresses vasculogenic mimicry and tumor aggressiveness in gastric carcinoma","volume":"18","author":"Dong","year":"2019","journal-title":"Oncol. Lett."},{"key":"10.1016\/j.ctarc.2026.101453_bib0079","doi-asserted-by":"crossref","DOI":"10.1136\/esmoopen-2019-000595","article-title":"Single-institute comparison of the efficacy of systemic chemotherapy for oesophagogastric junction adenocarcinoma and stomach adenocarscinoma in a metastatic setting","volume":"5","author":"Nakayama","year":"2020","journal-title":"ESMO Open"},{"key":"10.1016\/j.ctarc.2026.101453_bib0080","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1007\/s10120-020-01039-7","article-title":"Increased assessment of HER2 in metastatic gastroesophageal cancer patients: a nationwide population-based cohort study","volume":"23","author":"Dijksterhuis","year":"2020","journal-title":"Gastric Cancer"},{"key":"10.1016\/j.ctarc.2026.101453_bib0081","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1007\/s12029-019-00258-1","article-title":"Primary tumor location is a predictor of poor prognosis in patients with locally advanced esophagogastric cancer treated with perioperative chemotherapy","volume":"51","author":"Felismino","year":"2020","journal-title":"J. Gastrointest. Cancer"},{"key":"10.1016\/j.ctarc.2026.101453_bib0082","article-title":"Impact of HER2 status in resected gastric or gastroesophageal junction adenocarcinoma in a Western population","volume":"14","author":"Lago","year":"2020","journal-title":"Ecancermedicalscience"},{"key":"10.1016\/j.ctarc.2026.101453_bib0083","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1093\/abbs\/gmab026","article-title":"Amplification and expression of c-MET correlate with poor prognosis of patients with gastric cancer and upregulate the expression of PDL1","volume":"53","author":"Yang","year":"2021","journal-title":"Acta Biochim. Biophys. Sin (Shanghai)"},{"key":"10.1016\/j.ctarc.2026.101453_bib0084","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2022.108988","article-title":"Clinical significance of B7-H3 and HER2 co-expression and therapeutic value of combination treatment in gastric cancer","volume":"110","author":"Shao","year":"2022","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.ctarc.2026.101453_bib0085","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12876-022-02309-7","article-title":"Relationship between HER2 overexpression and long-term outcomes of early gastric cancer: a prospective observational study with a 6-year follow-up","volume":"22","author":"Li","year":"2022","journal-title":"BMC Gastroenterol."},{"key":"10.1016\/j.ctarc.2026.101453_bib0086","doi-asserted-by":"crossref","first-page":"518","DOI":"10.20892\/j.issn.2095-3941.2020.0636","article-title":"Is adjuvant chemotherapy necessary for early gastric cancer?","volume":"19","author":"Mei","year":"2021","journal-title":"Cancer Biol. Med."},{"key":"10.1016\/j.ctarc.2026.101453_bib0087","doi-asserted-by":"crossref","first-page":"813","DOI":"10.3390\/ijms24010813","article-title":"Clinical significance of molecular subtypes in western advanced gastric cancer: a real-world multicenter experience","volume":"24","author":"Salati","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ctarc.2026.101453_bib0088","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1097\/JS9.0000000000000370","article-title":"Impact of HER2 on prognosis and benefit from adjuvant chemotherapy in stage II\/III gastric cancer patients: a multicenter observational study","volume":"109","author":"Gao","year":"2023","journal-title":"Int. J. Surg."},{"key":"10.1016\/j.ctarc.2026.101453_bib0089","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2023.101582","article-title":"Incidence, clinicopathological features, and clinical outcomes of low HER2 expressed, inoperable, advanced, or recurrent gastric\/gastroesophageal junction adenocarcinoma","volume":"8","author":"Nakayama","year":"2023","journal-title":"ESMO Open"},{"key":"10.1016\/j.ctarc.2026.101453_bib0090","first-page":"1547","article-title":"The prognostic significance of HER2 positivity for advanced gastric cancer patients undergoing first-line modified FOLFOX-6 regimen","volume":"32","author":"Kim","year":"2012","journal-title":"Anticancer Res."},{"key":"10.1016\/j.ctarc.2026.101453_bib0091","first-page":"943","article-title":"HER 2\/neu protein expression in gastric cancer is associated with poor survival","volume":"2","author":"Xie","year":"2009","journal-title":"Mol. Med. Rep."},{"key":"10.1016\/j.ctarc.2026.101453_bib0092","first-page":"1972","article-title":"Overexpression of her-2 associated with the progression of esophageal cancer patients","volume":"60","author":"Wang","year":"2013","journal-title":"Hepatogastroenterology"},{"key":"10.1016\/j.ctarc.2026.101453_bib0093","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2018\/1505428","article-title":"Human epidermal growth factor receptor 2 status in gastric carcinomas with distinctive prevalent cribriform component","volume":"2018","author":"Ieni","year":"2018","journal-title":"Dis. Markers"},{"key":"10.1016\/j.ctarc.2026.101453_bib0094","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1056\/NEJM200103153441101","article-title":"Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2","volume":"344","author":"Slamon","year":"2001","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ctarc.2026.101453_bib0095","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1056\/NEJMoa052122","article-title":"Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer","volume":"353","author":"Romond","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ctarc.2026.101453_bib0096","doi-asserted-by":"crossref","DOI":"10.1186\/s12957-017-1132-5","article-title":"The clinicopathological parameters and prognostic significance of HER2 expression in gastric cancer patients: a meta-analysis of literature","volume":"15","author":"Lei","year":"2017","journal-title":"World J. Surg. Oncol."},{"key":"10.1016\/j.ctarc.2026.101453_bib0097","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1080\/13543784.2017.1315406","article-title":"Perspectives of HER2-targeting in gastric and esophageal cancer","volume":"26","author":"Gerson","year":"2017","journal-title":"Expert Opin. Investig. Drugs"},{"key":"10.1016\/j.ctarc.2026.101453_bib0098","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.3390\/jcm12041633","article-title":"Simpson\u2019s paradox in clinical research: a cautionary tale","volume":"12","author":"Bonovas","year":"2023","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.ctarc.2026.101453_bib0099","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1200\/JCO.22.00575","article-title":"Trastuzumab deruxtecan in anti-Human epidermal growth factor receptor 2 treatment-naive patients with Human epidermal growth factor receptor 2-low gastric or gastroesophageal junction adenocarcinoma: exploratory cohort results in a phase II trial","volume":"41","author":"Yamaguchi","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ctarc.2026.101453_bib0100","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2021.102249","article-title":"A systematic review of HER2 blockade for the curative treatment of gastroesophageal adenocarcinoma: successes achieved and opportunities ahead","volume":"99","author":"Stroes","year":"2021","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.ctarc.2026.101453_bib0101","article-title":"FLOT versus FLOT\/Trastuzumab\/Pertuzumab perioperative therapy of Human epidermal growth factor receptor 2-positive resectable esophagogastric adenocarcinoma: a randomized Phase II trial of the AIO EGA Study Group","volume":"69","author":"Hofheinz","year":"2022","journal-title":"J. Clin. Oncol."}],"container-title":["Cancer Treatment and Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468294226003631?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468294226003631?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T20:23:32Z","timestamp":1791663812000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2468294226003631"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"references-count":101,"alternative-id":["S2468294226003631"],"URL":"https:\/\/doi.org\/10.1016\/j.ctarc.2026.101453","relation":{},"ISSN":["2468-2942"],"issn-type":[{"value":"2468-2942","type":"print"}],"subject":[],"published":{"date-parts":[[2026]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The prognostic value of HER2 in gastroesophageal adenocarcinoma \u2013 a meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Cancer Treatment and Research Communications","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctarc.2026.101453","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"101453"}}